FDA grants fast track designation to nipocalimab for Sjögren’s disease
Nipocalimab, an experimental antibody-based therapy being developed by Johnson & Johnson, was granted fast track status by the U.S. Food and Drug Administration (FDA) for adults with moderate to severe Sjögren’s disease. Fast track status is given to candidate therapies for serious health conditions with the…